Skip to content

CYPH CYPH Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Amgen logo
AmgenAMGN
$559M+10.0%
MicroStrategy logo
MicroStrategyMSTR
$2.21B+3,561%
Ziff Davis logo
Ziff DavisZD
$519.72M+26.2%
Zscaler logo
ZscalerZS
$982.11M-50.7%

Other financials

Income statement

See full
Revenue$375.0K
Operating income-$4.8M+69.7%
Net income-$77.2M-400%
EPS (diluted)-$0.46-24.3%

Balance sheet

See full
Total debt$38.0K-75.3%
Total equity$84.4M+305%
Total assets$87.4M+151%

Cash flow

See full
Operating cash flow-$3.4M+76.3%

Valuation

See full
Market cap$65.19M-58.2%
Enterprise value$58.54M
P/S43.5×

Profitability

See full
Operating margin-2,761.7%
Net margin-2,705.8%

Returns & leverage

See full
Return on equity-108.2%-34.4pp
Debt / equity0.0×
Current ratio27.3×+24.9×

Where this comes from

Reported directly by CYPH in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: CYPH’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CYPH's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CYPH's cash & equivalents?
CYPH (CYPH) reported cash & equivalents of $6.69M in Q1 2026.
How has CYPH's cash & equivalents changed year-over-year?
CYPH's cash & equivalents decreased by 79.6% year-over-year, from $32.71M to $6.69M.
What is the long-term trend for CYPH's cash & equivalents?
Over 4 years (2021 to 2025), CYPH's cash & equivalents has grown at a -40.9% compound annual growth rate (CAGR), from $114.92M to $14.04M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.